94568-51-1

Basic information

• Product Name: Benzenemethanamine, 3-amino-4-chloro-
• CAS NO: 94568-51-1
• Molecular Formula: C7H9ClN2
• Molecular Weight: 156.615
• Mol File: 94568-51-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenemethanamine, 3-amino-4-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 3-amino-4-chloro-(94568-51-1)
• EPA Substance Registry System: Benzenemethanamine, 3-amino-4-chloro-(94568-51-1)

Safety Data

• Hazardous Substances Data: 94568-51-1(Hazardous Substances Data)

Upstream product

• 53312-79-1 3-amino-4-chloro-benzonitrile 
• 19694-10-1 4-chloro-3-amino-benzoic acid amide 

Downstream Products

• 180081-30-5 N-(3-amino-4-chlorophenylmethyl)carbamic acid t-butyl ester 
• 1242268-54-7 N-(4-chloro-3-aminobenzyl)-1-methylcyclohexylamide 
• 1431959-23-7 N-(5-((3-((1H-pyrrolo[2,3-b]pyridin-4-yl)methyl)thioureido)methyl)-2-chlorophenyl)acrylamide trifluoroacetate 
• 1431960-51-8 C₁₆H₁₆ClN₅S 

Relevant articles and documents

CHEMICAL COMPOUNDS

The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: wherein D, L, M, W, X, Y, and Z are defined herein. The compounds of the invention are inhibitors of DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b- and are useful in the treatment of cancer and hyperproliferative diseases. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention

Synthesis of potent and selective 2-azepanone inhibitors of human tryptase

The serine protease tryptase has been associated with a broad range of allergic and inflammatory diseases and, in particular, has been implicated as a critical mediator of asthma. The inhibition of tryptase therefore has the potential to be a valuable therapy for asthma. The synthesis, employing solution phase parallel methods, and SAR of a series of novel 2-azepanone tryptase inhibitors are presented. A member of this series, 8t, was identified as a potent inhibitor of human tryptase (IC50=38 nM) with selectivity ≤330-fold versus related serine proteases (trypsin, plasmin, uPA, tPA, APC, alpha-thrombin, and FXa).